227 results on '"Ruvolo, Vivian R."'
Search Results
2. Correction: Mitochondrial regulation of GPX4 inhibition–mediated ferroptosis in acute myeloid leukemia
3. Chromatin Profiles Are Prognostic of Clinical Response to Bortezomib-Containing Chemotherapy in Pediatric Acute Myeloid Leukemia: Results from the COG AAML1031 Trial
4. Correction: Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia
5. Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia
6. Inhibition of translation initiation factor eIF4a inactivates heat shock factor 1 (HSF1) and exerts anti-leukemia activity in AML
7. Mitochondrial regulation of GPX4 inhibition–mediated ferroptosis in acute myeloid leukemia
8. Enhanced TP53 reactivation disrupts MYC transcriptional program and overcomes venetoclax resistance in acute myeloid leukemias
9. LGALS3 is connected to CD74 in a previously unknown protein network that is associated with poor survival in patients with AML
10. AML-147 C-MYC Targeting by Degradation: Novel Dual c-Myc/GSPT1 Degrader GT19715 Exerts Profound Cell Kill In Vitro and In Vivo in Acute Myeloid Leukemia and Lymphomas
11. Supplementary Tables 1-9 from Targeting Unc51-like Autophagy Activating Kinase 1 (ULK1) Overcomes Adaptive Drug Resistance in Acute Myelogenous Leukemia
12. Abstract A31: C-MYC Targeting by Degradation: Novel Dual c-MYC/GSPT1 Degrader GT19715 Induces TP53-independent Cell Death in MYC-amplified Acute Myeloid Leukemia and Lymphomas
13. Data from Targeting Unc51-like Autophagy Activating Kinase 1 (ULK1) Overcomes Adaptive Drug Resistance in Acute Myelogenous Leukemia
14. Supplementary Figures 1-8 from Targeting Unc51-like Autophagy Activating Kinase 1 (ULK1) Overcomes Adaptive Drug Resistance in Acute Myelogenous Leukemia
15. Data from Evaluation of Apoptosis Induction by Concomitant Inhibition of MEK, mTOR, and Bcl-2 in Human Acute Myelogenous Leukemia Cells
16. Data from Focal Adhesion Kinase as a Potential Target in AML and MDS
17. Supplementary Tables 1 and 2 and Supplementary Figures 1 through 7 from Evaluation of Apoptosis Induction by Concomitant Inhibition of MEK, mTOR, and Bcl-2 in Human Acute Myelogenous Leukemia Cells
18. Supplementary Fig. S1 from Focal Adhesion Kinase as a Potential Target in AML and MDS
19. Supplemental Figure 1 from Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers
20. Supplemental Figure 3 from Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers
21. Supplemental Figure 2 from Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers
22. Supplemental Figure 4 from Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers
23. Supplemental Figure 5 from Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers
24. Supplementary Tables 1 and 2 and Supplementary Figures 1 through 5 from The Dual MEK/FLT3 Inhibitor E6201 Exerts Cytotoxic Activity against Acute Myeloid Leukemia Cells Harboring Resistance-Conferring FLT3 Mutations
25. Data from The Dual MEK/FLT3 Inhibitor E6201 Exerts Cytotoxic Activity against Acute Myeloid Leukemia Cells Harboring Resistance-Conferring FLT3 Mutations
26. Targeting Unc51-like Autophagy Activating Kinase 1 (ULK1) Overcomes Adaptive Drug Resistance in Acute Myelogenous Leukemia
27. Atg7 suppression enhances chemotherapeutic agent sensitivity and overcomes stroma-mediated chemoresistance in acute myeloid leukemia
28. Phosphorylation of GSK3α/β correlates with activation of AKT and is prognostic for poor overall survival in acute myeloid leukemia patients
29. Inhibition of Mcl-1 with the pan–Bcl-2 family inhibitor (–)BI97D6 overcomes ABT-737 resistance in acute myeloid leukemia
30. Poster: AML-147 C-MYC Targeting by Degradation: Novel Dual c-Myc/GSPT1 Degrader GT19715 Exerts Profound Cell Kill In Vitro and In Vivo in Acute Myeloid Leukemia and Lymphomas
31. C-MYC Targeting by Degradation: Novel Dual c-Myc/GSPT1 Degrader GT19715 Exerts Profound Cell Kill in vitro and in vivo in Acute Myeloid Leukemia and Lymphomas
32. Enhanced TP53 Reactivation Disrupts MYC Transcriptional Program and Overcomes Venetoclax Resistance in Acute Myeloid Leukemias
33. AXL/MERTK inhibitor ONO-7475 potently synergizes with venetoclax and overcomes venetoclax resistance to kill FLT3-ITD acute myeloid leukemia
34. Analysis of Malarial Transcripts Using cDNA-Directed Polymerase Chain Reaction
35. LGALS1 acts as a pro-survival molecule in AML
36. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia
37. High incidence of IDH mutations in acute myeloid leukaemia with cuplike nuclei
38. Abstract 2720: Mitochondrial ClpP-mediated proteolysis induces selective cancer cell lethality
39. Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia models
40. Mitochondrial ClpP-Mediated Proteolysis Induces Selective Cancer Cell Lethality
41. A miR-155/TP53 regulatory feedback loop involved in resistance to therapy in lung cancer and leukemia
42. Role of MSC-derived galectin 3 in the AML microenvironment
43. Distinct protein signatures of acute myeloid leukemia bone marrow-derived stromal cells are prognostic for patient survival
44. MCL-1 Up-Regulation through MAPK Activation Confers Acquired Resistance to BCL-2 Inhibitor ABT-199 in Pre-Clinical AML Models
45. Anexelekto/MER tyrosine kinase inhibitor ONO-7475 arrests growth and kills FMS-like tyrosine kinase 3-internal tandem duplication mutant acute myeloid leukemia cells by diverse mechanisms
46. Targeting MAPK Signaling Pathway with Cobimetinib (GDC-0973) Enhances Anti-Leukemia Efficacy of Venetoclax (ABT-199/GDC-0199) in Acute Myeloid Leukemia Models
47. Targeting signaling and apoptotic pathways involved in chemotherapeutic drug-resistance of hematopoietic cells
48. Focal Adhesion Kinase as a Potential Target in AML and MDS
49. Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers
50. Combination of galectin inhibitor GCS-100 and BH3 mimetics eliminates both p53 wild type and p53 null AML cells
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.